Researchers took the psilocybin-making genes from P. cubensis and put them into S. cerevisiae allowing them to produce psilocybin, several of its analogs, and a “new to nature” compound.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Understanding the potency of the compounds in nature’s cocktails is essential for formulating effective doses.
Severe side effects associated with 5-HT2B agonist drugs have dampened the interest of researchers. The therapeutic potential of psychedelics provides incentive for taking it up again.
Research is revealing that the psychedelic effect is due to much more than 5-HT2A activation.
Yes, based on its effects. But it doesn’t work via the serotonin 5-HT2A receptor like other psychedelics.
Scientists Synthesize and Test the Magic Mushroom Compounds Baeocystin, Norbaeocystin, Norpsilocin, and Aeruginascin
This work is a giant step forward for psychedelic research.
Activation of neuronal 5-HT1A receptors causes hyperpolarization and inhibition of cellular signaling.
Technically the answer is no, but subjective experiences may vary.
The 5-HT2A receptor is central to the effects of many psychedelics, but it may not be the only receptor involved.